(1) This instrument is the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 1) 2026.

(2) This instrument may also be cited as PB 8 of 2026.

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	The day after this instrument is registered.
2. Schedule 1	1 August 2026	1 August 2026

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99ADHC(2) of the National Health Act 1953.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments—Additional designated brands effective from 1 August 2026

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1 Section 5 (after table item dealing with the brand Lax-Tab of the drug Bisacodyl in the form Tablet 5 mg)

Insert:

DBL Bleomycin Sulfate

Bleomycin

Powder for injection containing bleomycin sulfate 15,000 I.U.

Injection

2 Section 5 (after table item dealing with the brand Triumeq of the drug Dolutegravir with abacavir and lamivudine in the form Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg)

Insert:

Adriamycin	Doxorubicin	Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 50 mg in 25 mL single dose vial	Injection/Intravesical
Doxorubicin ACC	Doxorubicin	Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 mL single dose vial	Injection

3 Section 5 (after table item dealing with the brand Flucil of the drug Flucloxacillin in the form Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL)

Insert:

Fludarabine Juno	Fludarabine	Powder for I.V. injection containing fludarabine phosphate 50 mg	Injection
Fludarabine Ebewe	Fludarabine	Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL	Injection

4 Section 5 (after table item dealing with the brand Lasix of the drug Furosemide in the form Oral solution 10 mg per ml, 30 ml)

Insert:

Lasix

Furosemide

Injection 20 mg in 2 mL

Injection

5 Section 5 (after table item dealing with the brand Moduretic of the drug Hydrochlorothiazide with amiloride in the form Tablet containing hydrochlorothiazide 50 mg with amiloride hydrochloride 5 mg)

Insert:

Solu-Cortef	Hydrocortisone	Injection 100 mg (as sodium succinate) with 2 mL solvent	Injection
Solu-Cortef	Hydrocortisone	Injection 250 mg (as sodium succinate) with 2 mL solvent	Injection

6 Section 5 (after table item dealing with the brand Vancomycin Viatris of the drug Vancomycin with amiloride in the form Powder for injection 500 mg (500,000 I.U.) (as hydrochloride))

Insert:

DBL Vinblastine

Vinblastine

Solution for I.V. injection containing vinblastine sulfate 10 mg in 10 mL

Injection